<DOC>
	<DOC>NCT00392379</DOC>
	<brief_summary>This study will be a randomized, blinded, placebo-controlled two-group clinical trial. The independent variable is treatment assignment (active 4-mg nicotine lozenge vs. matching placebo lozenge), and the dependent variables are all tobacco and ST abstinence at 3 and 6 months. ST users will be randomly assigned to either the 4-mg active nicotine lozenge or matching placebo.</brief_summary>
	<brief_title>Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction</brief_title>
	<detailed_description>Smokeless tobacco (ST) users will be randomly assigned to either the 4-mg active nicotine lozenge or matching placebo. Both groups will receive a behavioral intervention. The two sites for this clinical trial will be the Mayo Clinic in Rochester, Minnesota (central coordinating site) and the Oregon Research Institute (ORI) in Eugene, OR. A total of 270 ST users will be recruited into this clinical trail. All subjects will be randomized to 4 mg Nicotine Lozenges (taken ad lib) or matching placebo. They will be on study medication for 12 weeks and followed up for 6 months from study enrollment</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Lobeline</mesh_term>
	<criteria>are at least 18 years of age; report smokeless tobacco (ST) as their primary tobacco of use; have used ST daily for the past 6 months; are in general good health (determined by medical history and screening physical examination); have been provided with, understand, and have signed the informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Tobacco use disorder</keyword>
	<keyword>Tobacco cessation</keyword>
</DOC>